Mutual of America Capital Management LLC Sells 302 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Mutual of America Capital Management LLC reduced its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 0.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 32,144 shares of the biotechnology company’s stock after selling 302 shares during the period. Mutual of America Capital Management LLC owned about 0.05% of Blueprint Medicines worth $2,973,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of BPMC. Triad Wealth Partners LLC bought a new position in Blueprint Medicines during the second quarter valued at $27,000. Covestor Ltd grew its stake in shares of Blueprint Medicines by 9,700.0% during the 1st quarter. Covestor Ltd now owns 294 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 291 shares during the period. Natixis purchased a new stake in Blueprint Medicines in the 1st quarter worth about $73,000. CWM LLC raised its stake in Blueprint Medicines by 114.6% in the 2nd quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock valued at $119,000 after acquiring an additional 590 shares during the period. Finally, Van ECK Associates Corp lifted its holdings in Blueprint Medicines by 13.3% during the second quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $120,000 after purchasing an additional 131 shares during the last quarter.

Wall Street Analyst Weigh In

BPMC has been the topic of several research reports. Baird R W raised shares of Blueprint Medicines to a “strong-buy” rating in a research report on Friday, August 2nd. Wedbush restated an “outperform” rating and set a $135.00 target price on shares of Blueprint Medicines in a research report on Thursday, November 14th. Wells Fargo & Company reduced their price target on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. StockNews.com raised Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. Finally, Barclays lifted their target price on Blueprint Medicines from $75.00 to $105.00 and gave the company an “equal weight” rating in a report on Monday, July 29th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Blueprint Medicines currently has a consensus rating of “Moderate Buy” and an average price target of $122.11.

Insider Activity

In other news, insider Fouad Namouni sold 3,633 shares of the business’s stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the sale, the insider now owns 69,070 shares in the company, valued at approximately $6,169,332.40. The trade was a 5.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.21% of the company’s stock.

Blueprint Medicines Trading Down 2.6 %

NASDAQ BPMC opened at $94.15 on Friday. Blueprint Medicines Co. has a 12 month low of $66.61 and a 12 month high of $121.90. The company’s 50-day moving average price is $90.36 and its 200-day moving average price is $98.53. The stock has a market cap of $5.98 billion, a PE ratio of -44.62 and a beta of 0.59. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. During the same period last year, the company posted ($2.20) earnings per share. The company’s quarterly revenue was up 126.5% compared to the same quarter last year. Equities research analysts forecast that Blueprint Medicines Co. will post -3.68 earnings per share for the current year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.